CHITOSE and FUJIFILM Biosciences Form Strategic Alliance to Drive Global Innovation and Biopharmaceutical Manufacturing
Collaboration formed to accelerate biopharmaceutical manufacturing combining high performing CHO-MK cells and GMP-manufactured culture media
KAWASAKI, Japan and SANTA ANA, California. USA – Chitose Laboratory Corp., (CHITOSE), a leading company of the bioeconomy and provider of advanced cell line development services, and FUJIFILM Biosciences Inc., a global leader in the innovation and manufacture of cell culture solutions for the life science market, today announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.
CHITOSE’s expertise in cell line development using the established CHO-MK cells aligns seamlessly with FUJIFILM Biosciences’ advanced culture media development and manufacturing capabilities. By combining these complementary capabilities, the alliance will help accelerate biopharmaceutical manufacturing processes and support the development of innovative solutions for the industry. The growth characteristics of CHO-MK cells cultured in the optimized AdaptPD CHO-MK Platform Medium A and AdaptPD CHO-MK Feed 1 have made it possible to generate highly productive cells, resulting in higher titers and quality of the biopharmaceutical products1.
With CHITOSE, its strength lies in the company’s proprietary CHO-MK cell line and high-expression vector system, which enable exceptional productivity and scalability for antibody and recombinant protein production. This advantage positions CHITOSE as a key innovator in reducing manufacturing time and costs.
“Together, the combined expertise of CHITOSE and FUJIFILM Biosciences is set to create comprehensive solutions that not only enhance manufacturing efficiencies but also provide an integrated approach to tackling challenges in the global biopharma landscape,” said Takayuki Horiuchi, chief technology officer at Chitose Laboratory Corp.
FUJIFILM Biosciences complements this innovation with its state-of-the-art GMP manufactured cell culture AdaptPD CHO-MK Platform Media, designed to optimize CHO-MK cell growth and productivity across diverse biopharmaceutical applications. Leveraging decades of expertise in life sciences, FUJIFILM Biosciences’ solutions ensure consistency and reliability at every stage of bioprocessing.
The collaboration brings together the unique strengths of both companies to improve the way medicines are produced, supporting the development of new therapies for patients worldwide and helping more people access life-saving treatments.
“We’re excited about this strategic alliance as it underscores a shared vision of advancing therapeutic development by providing solutions designed to meet the growing demand for making biopharmaceuticals more accessible for treating conditions,” said Yutaka Yamaguchi, chairman and chief executive officer at FUJIFILM Biosciences. “FUJIFILM Biosciences forms alliances with like-minded companies like CHITOSE to drive meaningful progress and to create a lasting impact across life sciences.”
About CHITOSE Stable Cell Line Development Service for Biopharmaceutical Production Chitose Laboratory Corp. provides stable cell line development services to generate Pre-Master Cell Banks expressing innovative proteins using their high-yield, fast-growing CHO-MK host cells and their original CS CHO expression vector. The CHO-MK host cell line, which is banked as a host cell bank for the production of biopharmaceuticals, is CHITOSE CHO host cell line that was developed for industrial applications from the primary cell culture of a healthy Chinese hamster ovary tissue.
For more information, please visit: https://chitose-bio.com/cld-service
CHITOSE Group Overview https://chitose-bio.com/
 |
CHITOSE Group is a family of biotechnology companies leading the global bioeconomy. To live in abundance beyond the next millennium using the ability of living things, CHITOSE pursues the possibilities of biotechnology through technological and business development collaborating with its business partners all over the world.
|
About CHITOSE BIO EVOLUTION PTE. LTD. (head office that oversees CHITOSE Group)
- Established in October, 2011
- Head Office located in Singapore
- CEO: Tomohiro FUJITA, Ph. D.
About CHITOSE Laboratory Corp. (a core company of CHITOSE Group that focuses on business and technological development)
- Established in November, 2002
- Head Office located in Kawasaki-city, Kanagawa Prefecture, Japan
- CEO: Tomohiro FUJITA, Ph. D.
- COO: Rie KUGIMIYA
About FUJIFILM Biosciences
With a foundation in cell culture that dates back to 1970, FUJIFILM Biosciences is a global, full spectrum supplier to the life sciences market, providing products and services that assist customers in advancing healthcare initiatives. With an expanding portfolio of applications supported that include life science and discovery research, cell and gene therapy, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers and manufacturers worldwide. For over 50 years, FUJIFILM Biosciences’ Mission has been to empower all who bring medicines and treatments to life with unmatched quality and responsiveness in its products and custom solutions, providing customers with the vital resources needed to enrich human lives through innovative, accessible therapies. The Company’s facilities adhere to both ISO and FDA regulations, with manufacturing facilities that follow cGMP guidelines in the USA, Japan, and the Netherlands, and a media optimization center in China. All sites prioritize strategies that adhere to the FUJIFILM Sustainability Value Plan 2030 for sustainable growth. FUJIFILM Biosciences operates as a subsidiary of FUJIFILM Holdings America Corporation under FUJIFILM Holdings Corporation.
For more information, please visit: fujifilmbiosciences.fujifilm.com
About FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of “giving our world more smiles,” we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD).
